Benjamin Landry, the General Counsel of $HCAT, sold 27,425 shares of the company on 12-05-2025 for an estimated $72,327. We received data on the trade from a recent SEC filing. This was a sale of approximately 21.5% of their shares of this class of stock. Following this trade, they now own 100,000 shares of this class of $HCAT stock.
$HCAT Insider Trading Activity
$HCAT insiders have traded $HCAT stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $HCAT stock by insiders over the last 6 months:
- JULIE LARSON-GREEN sold 47,997 shares for an estimated $128,348
- BENJAMIN LANDRY (General Counsel) has made 0 purchases and 2 sales selling 33,600 shares for an estimated $93,032.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$HCAT Hedge Fund Activity
We have seen 74 institutional investors add shares of $HCAT stock to their portfolio, and 96 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 2,085,392 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $7,861,927
- PORTOLAN CAPITAL MANAGEMENT, LLC removed 1,980,409 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,644,165
- MILLENNIUM MANAGEMENT LLC added 1,528,710 shares (+2513.3%) to their portfolio in Q3 2025, for an estimated $4,356,823
- FIRST LIGHT ASSET MANAGEMENT, LLC added 1,206,039 shares (+9.9%) to their portfolio in Q3 2025, for an estimated $3,437,211
- PRIMECAP MANAGEMENT CO/CA/ removed 617,620 shares (-31.1%) from their portfolio in Q3 2025, for an estimated $1,760,217
- BAIRD FINANCIAL GROUP, INC. added 617,183 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,758,971
- SCHRODER INVESTMENT MANAGEMENT GROUP removed 468,692 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,335,772
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$HCAT Revenue
$HCAT had revenues of $76.3M in Q3 2025. This is a decrease of -0.04% from the same period in the prior year.
You can track HCAT financials on Quiver Quantitative's HCAT stock page.
$HCAT Analyst Ratings
Wall Street analysts have issued reports on $HCAT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Keybanc issued a "Overweight" rating on 10/08/2025
- Canaccord Genuity issued a "Buy" rating on 08/29/2025
- Wells Fargo issued a "Overweight" rating on 08/11/2025
To track analyst ratings and price targets for $HCAT, check out Quiver Quantitative's $HCAT forecast page.
$HCAT Price Targets
Multiple analysts have issued price targets for $HCAT recently. We have seen 8 analysts offer price targets for $HCAT in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- David Grossman from Stifel set a target price of $3.75 on 11/11/2025
- Daniel Grosslight from Citigroup set a target price of $3.25 on 11/11/2025
- Stan Berenshteyn from Wells Fargo set a target price of $5.0 on 11/11/2025
- Elizabeth Anderson from Evercore ISI Group set a target price of $3.0 on 10/08/2025
- Scott Schoenhaus from Keybanc set a target price of $4.0 on 10/08/2025
- Sarah James from Cantor Fitzgerald set a target price of $4.0 on 10/07/2025
- Richard Close from Canaccord Genuity set a target price of $5.0 on 08/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
